A Visionary Leader in Science and Skincare Innovation

Dr. Annette Tobia, Ph.D., is the founder and driving force behind Dynamis Skin Science, the parent organization of MEG 21. With a diverse and accomplished background as a research scientist, attorney, and entrepreneur, Dr. Tobia has dedicated her career to advancing health and well-being through science. Her lifelong passion for contributing to the well-being of others has led to groundbreaking discoveries in skincare, particularly in the area of glycation and its effects on aging skin.

Pioneering Discoveries at Fox Chase Cancer Center

Dr. Tobia's journey in skincare innovation began in 1997 when the Fox Chase Cancer Center in Philadelphia invited her to explore their research efforts to identify technology that could be commercialized. This invitation led to the founding of Dynamis Therapeutics, a company originally focused on diabetes-related discoveries. In 2001, Dr. Tobia and her team of chemists at Fox Chase Cancer Center uncovered the impact of toxic sugars on the skin. This discovery led to the development of Supplamine®, a powerful and patented ingredient that removes these toxic sugars, which is now a cornerstone of the MEG 21 skincare line.

Leadership and Experience

For over 27 years, Dr. Tobia has served as the Founder, President, and CEO of MEG 21 with Supplamine®, guiding the company from its inception to its current status as a leader in anti-glycation skincare. Under her leadership, transitioned from a virtual setup to an independent entity, and continues to advance product discovery, development, and pharmaceutical innovations.

Before founding Dynamis Therapeutics, Dr. Tobia was a Managing Partner at QED Technologies, where she played a key role in managing Arcturus Pharmaceutical Co., a dermatology company. Her work included coordinating clinical trials for skin treatments, consulting for biotechnology and pharmaceutical companies, and setting business and patent strategies.

Her career also includes significant leadership roles, such as Senior Vice President and General Counsel at British Technology Group, USA, where she managed a $75 million technology transfer company and was responsible for key licensing activities. She also served as Counsel to the President of Bristol-Myers Squibb Institute for Medical Research, overseeing legal affairs related to technology transfer, patents, and molecular biology.

Academic Excellence

Dr. Tobia's academic achievements are as impressive as her professional accomplishments. She earned her Juris Doctor (J.D.) from Rutgers Law School in 1979. She holds a Ph.D. and a Master's Degree from New York University's Department of Biology. Additionally, she was a Postdoctoral Fellow in the Department of Chemical Biology at Rockefeller University. Her academic journey began with a Bachelor's in Biology and Chemistry from Hunter College.

Continuing the Legacy

Today, Dr. Tobia continues to lead MEG 21 with the same passion and dedication that have defined her career. Her commitment to scientific integrity and innovation ensures that MEG 21 remains at the cutting edge of skincare, offering effective solutions backed by rigorous research and clinical validation.

A Lasting Impact

Through her leadership, MEG 21 with Supplamine® has become the most scientifically advanced anti-glycation skincare brand. Dr. Tobia's contributions to science and skincare are a testament to her vision and unwavering commitment to improving the health and beauty of those around her.

Connect with Dr. Annette Tobia, Ph.D.

To learn more about Dr. Tobia's professional journey and achievements, visit her LinkedIn Profile.